| Drug General Information |
| Drug ID |
D07OXC
|
| Former ID |
DIB018829
|
| Drug Name |
AM7
|
| Synonyms |
pyrimidone, 22; AM 7; AM-7
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
|
| Formula |
C35H35FN4O5
|
| InChI |
InChI=1S/C35H35FN4O5/c1-39-34(19-24-7-4-3-5-8-24)38-23-27(35(39)41)25-9-10-31(28(36)20-25)45-30-11-12-37-29-22-33(32(42-2)21-26(29)30)44-16-6-13-40-14-17-43-18-15-40/h3-5,7-12,20-23H,6,13-19H2,1-2H3
|
| InChIKey |
PEGWVOKOYYAQEV-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
16753545, 23752689, 29196123, 56269702, 80417612, 103606276, 137184084, 140427670, 227761684, 246192956, 252166504
|
| Target and Pathway |
| Target(s) |
Hepatocyte growth factor receptor |
Target Info |
Inhibitor |
[2]
|
|---|
|
KEGG Pathway
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
Endocytosis
|
|
PI3K-Akt signaling pathway
|
|
Axon guidance
|
|
Focal adhesion
|
|
Adherens junction
|
|
Bacterial invasion of epithelial cells
|
|
Epithelial cell signaling in Helicobacter pylori infection
|
|
Malaria
|
|
Pathways in cancer
|
|
Transcriptional misregulation in cancer
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancer
|
|
Renal cell carcinoma
|
|
Melanoma
|
|
Central carbon metabolism in cancer
|
|
Pathway Interaction Database
|
Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
|
|
Arf6 signaling events
|
|
Signaling events mediated by TCPTP
|
|
Posttranslational regulation of adherens junction stability and dissassembly
|
|
Direct p53 effectors
|
|
Syndecan-1-mediated signaling events
|
|
Stabilization and expansion of the E-cadherin adherens junction
|
|
a6b1 and a6b4 Integrin signaling
|
|
FGF signaling pathway
|
|
Regulation of retinoblastoma protein
|
|
Reactome
|
Sema4D mediated inhibition of cell attachment and migration
|
|
WikiPathways
|
TGF beta Signaling Pathway
|
|
Signaling of Hepatocyte Growth Factor Receptor
|
|
Focal Adhesion
|
|
Extracellular vesicle-mediated signaling in recipient cells
|
|
Signaling Pathways in Glioblastoma
|
|
miR-targeted genes in squamous cell - TarBase
|
|
miR-targeted genes in muscle cell - TarBase
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in epithelium - TarBase
|
|
Semaphorin interactions
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8292). |
|---|
| REF 2 | c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem. 2008 Feb 1;283(5):2675-83. Epub 2007 Nov 30. |
|---|
